Lilly launches its obesity drug in Denmark, Novo Nordisk's home market

Eli Lilly said it would launch its obesity drug, sold under the brand name Mounjaro, in Denmark starting the week of October 24, 2024, moving directly into the home market of its main rival, Novo Nordisk ^[1]. Novo Nordisk, maker of Wegovy and Ozempic, is Denmark's largest company and a major part of the country's economy, and the move was widely seen as symbolic given how much of Novo's success has come from Danish patients and shareholders ^[1].

According to a Lilly spokesperson, Mounjaro's monthly price in Denmark will run about 2,200 Danish crowns, or roughly $318.50 ^[1]. By comparison, Wegovy's monthly price in Denmark ranges from 1,313 crowns for a starter dose up to 2,353 crowns for the highest maintenance dose, based on figures from the Danish medicines agency ^[1]. Denmark's public health system does not generally cover weight-loss drugs, and the country's largest private health insurer, which covers about half the population, stopped paying for these drugs in 2023 because demand was so high ^[1].

Demand for Wegovy in Denmark has grown quickly. The number of users rose from about 60,000 in January 2024 to 90,000 by August, according to the Danish Health Data Authority, which also reported that 713,950 injection pens were dispensed in the first eight months of the year ^[1]. Roughly 19% of Denmark's population of about 6 million people has a body mass index of 30 or above, the threshold commonly used to define obesity ^[1].

Lilly's Danish launch follows recent rollouts of Mounjaro in Sweden and Finland, with Norway expected soon ^[1]. The drug has also reached the UK, Poland, Spain, Switzerland, and Germany ^[1]. Both Mounjaro and Wegovy are approved for weight loss alongside a reduced-calorie diet and more physical activity, and both come with other health benefits tied to reducing excess weight ^[1].

Why it matters for patients

This news centers on Denmark, not the United States, but it points to a broader pattern that can affect American patients too. As Lilly and Novo Nordisk compete more directly in more countries, both companies gain more real-world data on pricing, demand, and supply across different health systems ^[1]. Denmark's experience also shows how quickly demand for these drugs can outpace what private insurers are willing to cover, a tension that has played out in different forms in the US market as well ^[1]. The fact that Denmark's public system does not reimburse these drugs, and that a major private insurer there cut coverage in 2023 due to high demand, is a reminder that even in wealthy countries, insurance coverage for obesity drugs remains inconsistent ^[1]. For US readers, the underlying story is one of a genuinely global market: analysts cited in the reporting estimate the obesity-drug business could be worth $150 billion a year by the early 2030s, which is the kind of growth that tends to shape where companies invest in manufacturing and supply, potentially affecting availability elsewhere, including the US ^[1].

What happens next

The source does not specify further Danish rollout details beyond the initial launch date in late October 2024, nor does it describe any changes to US pricing or supply tied to this expansion ^[1]. Lilly's spokesperson noted that Mounjaro would soon launch in Norway, following its recent introduction in Sweden and Finland, but no exact date for Norway was given ^[1]. Whether Denmark's insurance landscape shifts in response to having two competing obesity drugs on the market is not addressed in the available reporting and is not yet known.